Linezolid-resistant cfr-positive MRSA, Italy

Journal of Antimicrobial Chemotherapy

Volumn 71, Issue 8, 2016, Pages 2349-2351

  Antonelli, Alberto ^a   D'Andrea, Marco Maria ^b   Galano, Angelo ^c   Borchi, Beatrice ^c   Brenciani, Andrea ^d   Vaggelli, Guendalina ^c   Cavallo, Annalisa ^c   Bartoloni, Alessandro ^a,c   Giovanetti, Eleonora ^d   Rossolini, Gian Maria ^a,b,c,e  

^a UNIVERSITY OF FLORENCE   (Italy)

^b UNIVERSITY OF SIENA   (Italy)

^c CAREGGI UNIVERSITY HOSPITAL   (Italy)

^d UNIVERSITÀ POLITECNICA DELLE MARCHE   (Italy)

^e IRCCS FONDAZIONE DON CARLO GNOCCHI   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

AMIKACIN; BACTERIAL PROTEIN; CEFTAROLINE; CEFTAZIDIME; CEFTOBIPROLE; CHLORAMPHENICOL; CLINDAMYCIN; COTRIMOXAZOLE; DALFOPRISTIN; DAPTOMYCIN; ERYTHROMYCIN; FUSIDIC ACID; LEVOFLOXACIN; LINCOSAMIDE; LINEZOLID; MEROPENEM; MINOCYCLINE; OXACILLIN; OXAZOLIDINONE DERIVATIVE; PLEUROMUTILIN; PROTEIN CFR; RIBOSOME PROTEIN; RIFAMPICIN; RNA 23S; TEICOPLANIN; TETRACYCLINE; UNCLASSIFIED DRUG; VANCOMYCIN; ANTIINFECTIVE AGENT; CFR PROTEIN, STAPHYLOCOCCUS AUREUS;

AMINO ACID SUBSTITUTION; ANTIBIOTIC RESISTANCE; CYSTIC FIBROSIS; GENE INSERTION SEQUENCE; GENE MUTATION; ITALY; LETTER; LINEZOLID RESISTANT METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS INFECTION; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PREVALENCE; BACTERIAL GENOME; CASE REPORT; COMPLICATION; DRUG EFFECTS; GENETICS; HIGH THROUGHPUT SEQUENCING; HUMAN; ISOLATION AND PURIFICATION; MICROBIAL SENSITIVITY TEST; MICROBIOLOGY; RESPIRATORY TRACT INFECTION; STAPHYLOCOCCUS INFECTION;

ANTI-BACTERIAL AGENTS; BACTERIAL PROTEINS; CYSTIC FIBROSIS; DRUG RESISTANCE, BACTERIAL; GENOME, BACTERIAL; HIGH-THROUGHPUT NUCLEOTIDE SEQUENCING; HUMANS; ITALY; LINEZOLID; METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS; MICROBIAL SENSITIVITY TESTS; RESPIRATORY TRACT INFECTIONS; STAPHYLOCOCCAL INFECTIONS;

EID: 84982218423     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkw108     Document Type: Letter

References (10)

1. Shen J, Wang Y, Schwarz S. Presence and dissemination of the multiresistance gene cfr in Gram-positive and Gram-negative bacteria. J Antimicrob Chemother 2013; 68: 1697-706.
2. Locke JB, Zuill DE, Sharm CR et al. Linezolid-resistant Staphylococcus aureus strain 1128105, the first known clinical isolate possessing the cfr multidrug resistance gene. Antimicrob Agents Chemother 2014; 58: 6592-8.
3. Gu B, Kelesidis T, Tsiodras S et al. The emerging problem of linezolidresistant Staphylococcus. J Antimicrob Chemother 2013; 68: 4-11.
4. Feßler AT, Calvo N, Gutiérrez N et al. Cfr-mediated linezolid resistance in methicillin-resistant Staphylococcus aureus and Staphylococcus haemolyticus associated with clinical infections in humans: two case reports. J Antimicrob Chemother 2014; 69: 268-70.
5. Caballero JD, Pastor MD, Vindel A et al. Emergence of cfr-mediated linezolid resistance in a methicillin-resistant Staphylococcus aureus epidemic clone isolated from patients with cystic fibrosis. Antimicrob Agents Chemother 2015; 60: 1878-82.
6. Klitgaard RN, Ntokou E, Nørgaard K et al. Mutations in the bacterial ribosomal protein L3 and their association with antibiotic resistance. Antimicrob Agents Chemother 2015; 59: 3518-28.
7. Griggs DJ, Marona H, Piddock LJ. Selection of moxifloxacin-resistant Staphylococcus aureus compared with five other fluoroquinolones. J Antimicrob Chemother 2003; 51: 1403-7.
8. Brenciani A, Morroni G, Pollini S et al. Characterization of novel conjugative multiresistance plasmids carrying cfr from linezolid-resistant Staphylococcus epidermidis clinical isolates from Italy. J Antimicrob Chemother 2016; 71: 307-13.
9. Campanile F, Bongiorno D, Perez M et al. Epidemiology of Staphylococcus aureus in Italy: First nationwide survey, 2012. J Glob Antimicrob Res 2015; 3: 247-54.
10. Mendes RE, Deshpande LM, Smyth DS et al. Characterization of baseline methicillin-resistant Staphylococcus aureus isolates recovered from phase IV clinical trial for linezolid. J Clin Microbiol 2010; 48: 568-74.